Press Release Service
![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Scribe Therapeutics
Main focus: Development of CasX for therapeutic use in genetic diseases
Company stage: Pre-clinical
Diseases: Amyotrophic lateral sclerosis (ALS), otherwise undisclosed
Genome editing tool: CRISPR-CasX
Funding stage: Private
Location: San Francisco Bay Area, California, United States
Website: https://www.scribetx.com/
Partners: Biogen
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_Scribe_Logo-e1592585747375_288341c00a_f812ad2038.png)
Scribe Therapeutics develops novel Cas variants, in particular the CasX enzyme, for the treatment of genetic diseases. The company has yet to disclose its pre-clinical pipeline. However, it has unveiled a collaboration with Biogen focusing on ALS.